Profile data is unavailable for this security.
About the company
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
- Revenue in USD (TTM)400.00k
- Net income in USD82.35m
- Incorporated1989
- Employees136.00
- LocationAbeona Therapeutics Inc6555 CARNEGIE AVE, 4TH FLOORCLEVELAND 44103United StatesUSA
- Phone+1 (646) 813-4701
- Fax+1 (302) 655-5049
- Websitehttps://abeonatherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BGM Group Ltd | 26.85m | -2.72m | 194.95m | 323.00 | -- | 0.6477 | -- | 7.26 | -0.2816 | -0.2816 | 1.38 | 1.85 | 0.2087 | 3.21 | 8.60 | 83,116.91 | -2.08 | -0.0792 | -2.36 | -0.1065 | 19.41 | 10.38 | -9.95 | -0.0921 | 1.45 | -0.3408 | 0.0087 | 2,560.18 | -45.99 | -11.45 | 81.46 | -- | 16.40 | -- |
| Journey Medical Corp | 59.40m | -8.66m | 220.51m | 41.00 | -- | 8.24 | -- | 3.71 | -0.3645 | -0.3645 | 2.58 | 0.982 | 0.796 | 1.79 | 4.15 | 1,448,756.00 | -11.61 | -22.37 | -22.74 | -50.55 | 64.40 | 59.45 | -14.58 | -27.43 | 1.12 | -3.30 | 0.4928 | -- | -29.11 | 9.96 | -280.79 | -- | 44.27 | -- |
| Mediwound Ltd | 20.93m | -20.60m | 223.11m | 111.00 | -- | 4.45 | -- | 10.66 | -1.90 | -1.90 | 1.93 | 3.91 | 0.2475 | 4.59 | 3.69 | 188,576.60 | -24.36 | -35.38 | -35.12 | -48.39 | 18.53 | 32.18 | -98.43 | -71.55 | 2.48 | -- | 0.1416 | -- | 8.22 | -8.65 | -350.03 | -- | 51.27 | -- |
| Coherus Oncology Inc | 83.57m | -187.47m | 246.63m | 161.00 | -- | 2.19 | -- | 2.95 | -1.62 | 1.33 | 0.721 | 0.7551 | 0.1636 | 1.76 | 0.9453 | 366,526.30 | -36.70 | -21.44 | -106.02 | -31.54 | 47.79 | 71.26 | -224.34 | -42.66 | 1.23 | -15.12 | 0.3656 | -- | 3.78 | -5.60 | 111.98 | -20.51 | -- | -- |
| Lifecore Biomedical Inc | -100.00bn | -100.00bn | 270.88m | 406.00 | -- | -- | -- | -- | -- | -- | -- | 0.9818 | -- | -- | -- | -- | -- | -7.91 | -- | -10.85 | -- | 32.86 | -- | -23.15 | 1.67 | -- | 0.787 | -- | 0.4725 | -4.24 | -575.39 | -- | -12.85 | -- |
| Abeona Therapeutics Inc | 400.00k | 82.35m | 274.21m | 136.00 | 4.58 | 1.55 | 3.24 | 685.52 | 1.11 | 1.11 | 0.0073 | 3.27 | 0.0023 | -- | 0.2478 | 2,941.18 | 46.83 | -62.23 | 52.94 | -78.23 | -122.00 | -- | 20,587.50 | -1,824.21 | 9.53 | -- | 0.1034 | -- | -100.00 | -- | -17.62 | -- | -17.78 | -- |
| Evolus Inc | 285.82m | -58.56m | 278.08m | 329.00 | -- | -- | -- | 0.9729 | -0.9125 | -0.9125 | 4.46 | -0.4441 | 1.27 | 4.09 | 6.01 | 860,912.60 | -26.11 | -37.04 | -36.48 | -57.14 | 65.83 | 65.19 | -20.49 | -51.26 | 1.53 | -2.13 | 1.25 | -- | 31.76 | 50.12 | 18.26 | -- | 1.10 | -- |
| Fennec Pharmaceuticals Inc | 38.79m | -6.94m | 280.74m | 36.00 | -- | -- | -- | 7.24 | -0.2524 | -0.2524 | 1.41 | -0.1601 | 0.7171 | 1.48 | 2.41 | -- | -12.83 | -55.15 | -15.26 | -64.98 | 93.12 | -- | -17.89 | -107.31 | 4.44 | -2.44 | 1.33 | -- | 123.69 | -- | 97.28 | -- | -- | -- |
| AC Immune SA | 5.61m | -92.28m | 289.18m | 133.00 | -- | 3.61 | -- | 51.52 | -0.9183 | -0.9183 | 0.0559 | 0.7984 | 0.021 | -- | 0.3392 | 42,203.34 | -34.57 | -27.41 | -66.37 | -30.60 | -- | -- | -1,643.94 | -505.58 | -- | -- | 0.0695 | -- | 84.51 | -24.38 | 6.12 | -- | -21.11 | -- |
| X4 Pharmaceuticals Inc | 33.98m | -95.10m | 297.28m | 143.00 | -- | 1.39 | -- | 8.75 | -10.50 | -10.50 | 2.94 | 2.45 | 0.1989 | 1.75 | 25.37 | 237,615.40 | -55.66 | -55.04 | -65.82 | -63.45 | 83.24 | -- | -279.86 | -6,897.81 | 5.48 | -19.26 | 0.5525 | -- | -- | -- | 62.98 | -- | 111.28 | -- |
| Opus Genetics Inc | 14.63m | -68.20m | 298.62m | 18.00 | -- | 46.84 | -- | 20.41 | -1.76 | -1.76 | 0.2952 | 0.0925 | 0.3825 | -- | 3.85 | 812,944.40 | -178.28 | -76.30 | -330.00 | -86.90 | -- | -- | -466.09 | -185.79 | -- | -- | 0.1518 | -- | -42.30 | -- | -476.13 | -- | -- | -- |
| Puma Biotechnology Inc | 228.37m | 31.11m | 326.63m | 179.00 | 10.52 | 2.48 | 7.77 | 1.43 | 0.6104 | 0.6104 | 4.51 | 2.59 | 1.06 | 8.17 | 5.33 | 1,275,816.00 | 14.48 | 4.80 | 24.66 | 8.38 | 74.53 | 74.14 | 13.62 | 4.58 | 1.93 | 14.66 | 0.1473 | 0.00 | -0.9099 | 0.2881 | 2.75 | -- | -67.65 | -- |
| Akebia Therapeutics Inc | 236.20m | -5.35m | 337.53m | 194.00 | -- | 10.26 | -- | 1.43 | -0.0179 | -0.0179 | 0.8976 | 0.1229 | 0.791 | 2.55 | 5.80 | 1,217,505.00 | -1.79 | -27.07 | -3.03 | -45.24 | 82.83 | 78.83 | -2.26 | -45.92 | 1.46 | 1.07 | 0.8558 | -- | 47.46 | -4.33 | 92.30 | -- | 91.19 | -- |
Data as of Mar 03 2026. Currency figures normalised to Abeona Therapeutics Inc's reporting currency: US Dollar USD
39.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nantahala Capital Management LLCas of 31 Dec 2025 | 4.96m | 9.16% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 2.89m | 5.34% |
| Suvretta Capital Management LLCas of 31 Dec 2025 | 2.68m | 4.94% |
| Cable Car Capital LPas of 31 Dec 2025 | 2.50m | 4.61% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.40m | 4.43% |
| AIGH Capital Management LLCas of 31 Dec 2025 | 2.00m | 3.69% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.14m | 2.10% |
| Kennedy Capital Management LLCas of 31 Dec 2025 | 1.05m | 1.94% |
| Tang Capital Management LLCas of 31 Dec 2025 | 1.00m | 1.85% |
| Nan Fung Trinity (HK) Ltd.as of 31 Dec 2025 | 956.77k | 1.77% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
